In this 7th DDup issue, we delve into the unique new kidney platforms poised to change the trajectory of kidney disease research and therapeutics development. Evotec has embarked on a novel collaboration model with Kidney Research UK, University of Bristol, University of Cambridge, University of Nottingham and the Mario Negri Institute in Bergamo to develop unique proprietary platforms (NURTuRE and NEPLEX), as well as a joint venture, NephTec, to accelerate development of first-in-class therapeutics for kidney disease.
Evotec is continuing to expand its platform and employs patient-derived and multi-omics approaches to decode the biology of kidney disease and discover novel targets and biomarkers towards the next generation first-in-class kidney therapeutics.

Download full publication here